63725-51-9

Usage

Uses

Used in Pharmaceutical Research:
6-Chloro-1H-pyrazolo[3,4-b]pyridine is used as a building block in the synthesis of bioactive compounds for pharmaceutical applications. Its unique structure and potential biological activities make it a valuable research tool in the development of new drugs.
Used in Agrochemical Research:
In the agrochemical industry, 6-Chloro-1H-pyrazolo[3,4-b]pyridine is used as a starting material for the synthesis of various agrochemicals, such as pesticides and herbicides, due to its potential biological activities.
Used in Anti-Cancer Applications:
6-Chloro-1H-pyrazolo[3,4-b]pyridine is studied for its potential as an anti-cancer agent. Its unique chemical structure and biological activities make it a promising candidate for the development of new cancer therapies.
Used in Anti-Inflammatory Applications:
6-Chloro-1H-pyrazolo[3,4-b]pyridine is also being investigated for its potential as an anti-inflammatory agent. Its ability to modulate inflammatory pathways could lead to the development of new treatments for inflammatory diseases.
Used as a Research Tool:
6-Chloro-1H-pyrazolo[3,4-b]pyridine serves as a valuable research tool in the development of new drugs. Its unique properties and potential applications in various fields make it an important compound for further investigation and exploration.

InChI:InChI=1/C6H4ClN3/c7-5-2-1-4-3-8-10-6(4)9-5/h1-3H,(H,8,9,10)

Upstream product

• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 924909-11-5 1H-pyrazolo[3,4-b]pyridine 7-oxide 
• 55304-73-9 2,6-dichloro-pyridine-3-carbaldehyde 
• 2402-78-0 2,6-dichloropyridine 
• 1093880-37-5 6-chloro-2-fluoropyridine-3-carboxaldehyde 

Downstream Products

• 1357946-70-3 3-bromo-6-chloro-1H-pyrazolo[3,4-b]pyridine 
• 1614233-32-7 6-(2,6-difluoro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine 
• 63725-52-0 6-chloro-1-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1616099-29-6 6-chloro-2-methyl-2H-pyrazolo[3,4-b]pyridine 
• 2105905-46-0 4,6-dichloro-1H-pyrazolo[3,4-b]pyridine 

Relevant academic research and scientific papers

Development of a Scalable Method for Manufacturing the Central Core of CD73 Inhibitor AB680

AB680 is a highly potent CD73 small molecule inhibitor discovered and developed by Arcus Biosciences, currently in clinical trials for the treatment of pancreatic cancer. Here, we report the development of a scalable and practical method for the manufacturing of the azaindazole central core. This synthesis features an N-oxide formation followed by an α-chlorination with POCl3 leading to the formation of 4,6-dichloro-1H-pyrazolo[3,4-b]pyridine 1 in high yield and 99.5% UV purity. This method was successfully performed on multikilogram scale to support the synthesis of AB680.

Synthetic method for 6-chloro-1H-pyrazolo[3,4-B]pyridine

The invention discloses a synthetic method for 6-chloro-1H-pyrazolo [3,4-B]pyridine. The synthetic method has the advantages that 2,6-dichloro-3-pyridinecarboxaldehyde and hydrazine hydrate which arecheap and easily obtained are taken as raw materials so as to prepare the 6-chloro-1H-pyrazolo[3,4-B]pyridine, the yield is not lower than 70%, the synthetic reaction conditions are mild, the purification is simple, a product is prepared with relatively high yield and high purity, the synthetic method is suitable for process scale-up, and therefore the problems that in the prior art, the raw materials are expensive, and the yield is low can be solved.

Heterocyclic compound used as MNK inhibitor

The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.

INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS

The present invention provides indazole and aza indazole compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.